Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis. A new systematic review and meta-analysis suggests ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
A new study suggests that COVID-19 may slightly increase the risk of lung cancer by triggering a biological chain reaction in ...
Born with cystic fibrosis, Joseph McCanne underwent two double lung transplants — and the medication damaged his kidneys 11Alive/YouTube Sherry Petty donated her kidney to her son Joseph McCanne, who ...
Scientists think they have discovered the reason pulmonary fibrosis patients get worse and don’t heal. Pulmonary fibrosis leads to scar tissue development in the lungs that persists until patients ...
Tiny plastic fragments small enough to reach the deepest regions of the lungs have been found embedded in human tissue, and a growing body of laboratory research now links these particles to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results